ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
The Danish biotech start-up 21st.Bio has raised $97 million to build its first manufacturing site. The company helps clients choose the best organism to produce a desired chemical and then optimizes the strain for large-scale production. 21st.Bio is based on technology from the Danish biotech company Novozymes, which has a stake in the firm and could earn royalties on products made by 21st.Bio clients.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X